The Expression And Significance Of Cysteine Rich 61 And Ascular Endothelial Growth Factor In Myelodysplastic Syndrome

Background and Objective:Myelodysplastic syndrome (MDS), a clonal hematopoietic stem cell disorder, may progress to acute leukemia in some cases. At present,the pathogenesis of myelodysplastic syndromes are not clear. Angiogenesis is the generation of new capillaries from preexisting blood vessels, is a multistep process. Angiogenesis is co-regulated by angiogenic factors and angiogenesis inhibitors. Moreover, large bodies of studies indicate that angiogenesis of capillaries is associated with the development of neoplastic lesions. Recently, a role for angiogenesis in the pathophysiology of hematologic malignancies has been suggested. Some investigators are interested in whether angiogenesis plays a role in the pathophysiology of MDS. Recent studies showed that the microvessels in the bone marrow of patients with MDS were higher than that in normal controls, but whether the microvessels in the bone marrow of patients with MDS is lower than that in acute myeloid leukemia remains poorly understood.Cysteine rich 61 (Cyr61) and vascular endothelial growth factor(VEGF), the mitogenic activator of vascular endothelial cell, play an important role in tumor angiogenesis. They are also closely related with occurrence and development of malignant blood diseases.This subject is to explore the expression of Cyr61 gene in myelodysplastic syndrome.To explore the correlation between overexpression of Cyr61 and occurrence and development of MDS, and to explore the relationship between Cyr61 and VEGF.To provide a theoretical basis for the mechanism of Cyr61 in the occurrence of MDS.Methods:Expressions of Cyr61 and VEGF gene mRNA and protein were detected in BMMNC from 28 patients with MDS and 22 cases of the control which included 12 cases of acute myeloid leukemia (AML),10 cases of normal volunteers by Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohisto-chemical S-P.Results:1. Expressions of Cyr61 and VEGFmRNA in BMMNC were significantly higher in MDS and AML patients than that in normal controls(P<0.05).2. Expressions of Cyr61 and VEGFmRNA were significantly higher in high risk group and AML group than that in low risk group(P<0.05).3. No significant difference of Cyr61 and VEGFmRNA was found between high risk MDS patients and acute myeloid leukemia patients.4. Expressions of Cyr61 and VEGF protein were higher in MDS patients than that in normal controls(P<0.05).5. The expressions of Cyr61 and VEGF protein were significantly higher in high risk group than that in low risk group(P<0.05).6. Expressions of Cyr61 and VEGF in MDS patients were significantly associated(r=0.8762,P<0.01).Conclusion:1. Overexpressions of Cyr61 and VEGF gene were related to the angiogenesis in the bone of MDS patients.2. The expression of Cyr61 gene is associated to the occurrence and development of MDS,and associated to the transformation to AML.3. Cyr61 may be a prognostic factor in myelodysplastic syndrome.4. Cyr61 may be a target of anti-angiogenic therapy for MDS, and provide a new way for treatment of MDS patients.